Coloplast needs financial tailwinds to reach upper end of forecast

In its current strategy, Strive25, Coloplast expects organic growth in the 8-10% range and an operating margin, EBIT, before special items of more than 30% after 2024/25.
Photo: Coloplast/pr
Photo: Coloplast/pr

Coloplast has decided to maintain its long-term forecast under the Strive25 strategy but meeting the upper end of the company’s organic growth expectations will require headwinds in China and within the Urology division to subside, CFO Anders Lonning-Skovgaard said at the company’s capital markets day. 

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading